Autopsy report · NCT00089128
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Cause of deathSlow enrollment
“Low accrual”
Life of this trial
- Registered 2 years 9 months after it had already started.
- Ran for about 7 years before it stopped.
- 16 participants enrolled.
- Results were posted on the registry 9 years 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Medical University of South Carolina
- Sponsor type
- University, hospital or other
- Conditions
- Bladder Cancer
- Interventions
- gemcitabine hydrochloride; irinotecan hydrochloride
- Participants
- 16
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.